Brighter tomorrow We are dedicated to revolutionizing the diagnosis and monitoring of life-altering diseases by advancing the science of epigenetics. Our mission is to save lives and improve outcomes for millions of people and animals worldwide. Imagine a world where diseases like cancer and sepsis can be diagnosed early and monitored easily using routine blood tests. That’s the world we’re trying to build by developing our innovative family of simple, easy to use, cost-effective Nu.Q® tests. Our patented Nucleosomics™ technology uses chromosomal structures called nucleosomes as biomarkers in cancer and other diseases. All the tests in our portfolio detect various characteristic changes in nucleosomes that occur from the earliest stages of disease, enabling early detection and potentially a better way to monitor disease progression and the patient’s response to treatment. Volition has four pillars of focus: Nu.Q®, Nu.Q® NETs, Nu.Q® Capture and Nu.Q® Vet. We are headquartered in Austin, Texas, with locations in Belgium, California, Singapore and the UK. We are listed on the New York Stock Exchange (NYSE AMERICAN) as VolitionRX Limited (VNRX).